A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Completed · Phase 2 · NCT02675231
Conditions: Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
At a glance
- Research payments reported, 2025
- $29,308
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 237
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Abemaciclib (drug), Trastuzumab (drug), Fulvestrant (drug), Standard of Care Single Agent Chemotherapy (drug)
- Dates
- Started 2016-05-23; completion 2023-11-09
- Results posted
- Yes
The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus physicians choice standard of care chemotherapy in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 positive (HER2+) locally advanced or metastatic breast cancer after prior exposure to at least two HER2-directed therapies for advanced disease.
From ClinicalTrials.gov, last updated 2024-11-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $29,308 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Tiffany Troso-sandoval, MD Medical Oncology · Commack, NY
- William R. Gwin III, MD Medical Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan-Kettering $20,788
- University of Washington Medical Ctr, WA $8,520
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.